RAF Kinase Pathway in HCC

Signaling Pathways for Cell Proliferation and Survival: RAF/MEK/ERK^1,2,3,4

Cell Signaling Overview

Recent advances in tumor biology are shedding new light on molecular events in the multistep etiology of hepatocellular carcinoma (HCC). The mitogen-activated protein kinase (MAPK) signaling pathway RAS/RAF/MEK/ERK plays a key role in governing cell proliferation, differentiation, and survival.⁵ Furthermore, it has been reported that both angiogenesis and signaling through the RAF/MAP/ERK cascade may play critical roles in the development of HCC.⁶

It is now known that the pathway couples signals from cell surface receptors to gene-regulating nuclear transcription factors.⁷ The process begins with activation of the small G-protein RAS, which leads to the recruitment of RAF-1 to the inner surface of the cell membrane.⁸ RAF-1, in turn, phosphorylates MEK, which then phosphorylates and activates ERK downstream. Activated ERK translocates to the cell nucleus and regulates gene expression by interacting with various transcription factors.

Uncontrolled activation of this pathway or aberrant signaling could promote

• Cell immortalization
• Growth factor–independent proliferation and insensitivity to growth-inhibitory signals
• Inactivation of tumor suppressor genes
• Invasion and metastases (through stimulation of cellular motility and extracellular matrix remodeling)
• Angiogenesis through upregulation of proangiogenic factors
• Avoidance of apoptosis
• Resistance to radiation⁹

The RAS/RAF/MEK/ERK pathway is activated or expressed in many malignant tumors including HCC.⁶ Based on these processes, it has been shown that the RAS/RAF/MEK/ERK pathway plays a substantial role in the development of HCC.⁶ Furthermore, it has been reported that ERK expression in HCC is associated with tumor size, histologic progression, or vessel invasion, leading to induction of intrahepatic metastasis.¹⁰

Signal Transduction Inhibition as a Therapeutic Strategy

RAF kinase inhibitor protein (RKIP) is a cellular inhibitor of the RAS/RAF/MEK/ERK cascade, which prevents activation of MEK by RAF and downstream signal transduction.¹¹ However, RKIP expression has been shown to be markedly downregulated in HCC cell lines, which may contribute to elevated ERK activity in HCC.¹¹ In addition, another study reports an inverse relationship between the level of ERK phosphorylation and growth inhibition in HCC cell lines, suggesting a correlation between ERK phosphorylation levels and the proliferative potential of HCC cells.¹² Therefore, specifically inhibiting the RAF/MEK/ERK signaling pathway may contribute to the proapoptotic effects of therapies targeted toward this pathway.⁶ Furthermore, it has been shown that treating HCC cells with a MEK inhibitor has multiple anticancer effects.¹² Finally, therapies targeted toward the inhibition of both angiogenesis and RAF/MEK/ERK signaling represent novel approaches for the treatment of HCC.⁶

Read more about:

• Liver Cancer: Incidence and Prevalence
• Populations at Risk
• Commitment of Bayer and Onyx
• Professional Resources

References

1. Feitelson MA et al. Surg Clin N Am. 2004;84:339-354.
2. Thorgeirsson S, Grisham JW. Nat Genet. 2002;31:339-346.
3. Wiesenaure CA et al. J Am Coll Surg. 2004;198:410-421.
4. Hwang YH et al. Hepatol Res.2004;29:113-21.
5. Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J. 2000;351:289-305.
6. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res .2006;66:11851-11858.
7. McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Advan Enzyme Regul. 2006;46:249-279.
8. Lee HC, Tian B, Sedivy JM, Wands JR, Kim M. Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology . 2006;131:1208-1217.
9. Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther. 2005;4:677-685.
10. Osada S, Kanematsu M, Imai H, Goshima S, Sugiyama Y. Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma. J Am Coll Surg . 2005;201:405-411.
11. Schuierer MM, Bataille F, Weiss TS, Hellerbrand C, Bosserhoff AK. Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep. 2006;16:451-456.
12. Wiesenauer CA, Yip-Schneider MT, Wang Y, Schmidt CM. Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. J Am Coll Surg . 2004;198:410-421.